Senior Medical Director
Takeda Pharmaceutical Ltd.
Dr. Tara Robinson, MD, PhD, is currently a Senior Medical Director at Takeda Pharmaceutical Ltd. She earned her MD/PhD from Thomas Jefferson University, and then completed internal medicine residency and hematology fellowship at the Johns Hopkins Hospital, where she was also a faculty member until 2020. She then moved to industry at BioMarin and was the clinical development lead for valoctocogene roxaparvovec, the first gene therapy approved for hemophilia A. In her current role at Takeda, she is the clinical development lead for recombinant ADAMTS13, which is approved for congenital thrombotic thrombocytopenic purpura (TTP) and in development for immune TTP. Dr. Robinson is passionate about translating knowledge from the bench to the bedside, and creating novel therapeutics for patients with hematologic diseases.
Cell and Gene Therapy: Transforming Treatment Paradigms for Patient-Centric Care
Friday, April 4, 2025
10:00 AM - 2:00 PM East Coast USA Time